Endocrinology Search
Endocrinology Endocrinology
hyperprolactinemia
HYPERPROLACTINEMIA
Hyperprolactinemia is the presence of elevated prolactin levels that occurs in about one-thirds of patients w/ chronic kidney disease & resolves after successful transplantation.
It may cause visual field defects or headache in both men and women.
In women, signs and symptoms include menstrual irregularity, galactorrhea, infertility, vaginal dryness, dyspareunia, loss of libido and reduction in vertebral bone density (in sustained, pronounced hyperprolactinemia).
While in men, signs and symptoms include diminished libido, hypogonadism, gonadotrophin suppression, osteopenia, decreased muscle mass, and decreased facial hair that may occur in prolonged hyperprolactinemia.
Drug Information

Indication: Parkinson's disease. Menstrual disorders & infertility. Benign breast disease. Prolactinoma. Acromegaly.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Early antibiotic exposure not linked to childhood weight gain
Roshini Claire Anthony, 11 Apr 2016
Early antibiotic exposure (in the first 6 months of life) is not associated with childhood weight gain, according to a recent retrospective US study.
High seafood intake may increase sexual intercourse frequency, fecundity
02 Aug 2018
Men and women who regularly eat seafood appear to have higher sexual intercourse frequency (SIF) and fecundity in a large prospective cohort of couples attempting pregnancy, suggests a study.
Consumption of whole-grain rice lowers postprandial blood glucose response
29 Oct 2018
Whole-grain rice significantly reduces postprandial blood glucose response relative to white rice, results of a systematic review and meta-analysis have shown.
Parathyroid surgery better: bishosphonates did not reduce fracture risk in PHPT despite BMD gain
Pearl Toh, 30 Apr 2016
Parathyroid removal surgery, or parathyroidectomy, was associated with fewer fractures in primary hyperparathyroidism (PHPT) patients while bisphosphonate therapy was not, according to a study comparing the treatment methods.